A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients' perspective

Objective To assess tyrosine kinase inhibitor(TKI)treatment status in patients with chronic myeloid leukemia(CML)in China and analyze the response-associated factors.Methods From May to November in 2014,anonymous questionnaires were distributed to adult CML patients who were receiving TKI treatment all over China.

Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase

Objective To explore the impact of patient reported outcome of tyrosine kinase inhibitor(TKI)related side effects on daily life in Chinese patients with chronic myceloid leukemia(CML)in the chronic phase(CP).Methods From May to November in 2014。

A comparison of efficacy and safety between Chinese generic imatinib and branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase:a single-center prospective cohort study

Objective To compare the efficacy and safety between Chinese generic imatinib(Xinwei~,Jiansu Hansoh Pharmaceutical Group Co.,Ltd.)and branded imatinib(Glivec~,Novartis)in patients with newly-diagnosed chronic myeloid leukemia in chronic phase(CML-CP).Methods Patients with newly diagnosed CML-CP